Online inquiry

IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14571MR)

This product GTTS-WQ14571MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL), B cell acute lymphoblastic leukemia (B cell ALL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ14571MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ395MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ9995MR IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA KRN-23
GTTS-WQ15808MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA XmAb14045
GTTS-WQ3378MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AT-005
GTTS-WQ13528MR IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PRX-003
GTTS-WQ12830MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ONC-005
GTTS-WQ8113MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ4315MR IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BIVV009
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW